PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Cost reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive advantage potential.
41.00%
Growth of 41.00% versus flat Biotechnology gross profit. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-31.86%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
-15.50%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.75%
Operating expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-27.36%
Total costs reduction while Biotechnology median is 1.85%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
D&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency.
28.32%
EBITDA growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
27.93%
Operating income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
-5.21%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
29.77%
Pre-tax income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
128.31%
Tax expense change of 128.31% versus flat Biotechnology. Walter Schloss would verify strategy.
29.77%
Net income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
30.61%
EPS change of 30.61% versus flat Biotechnology. Walter Schloss would verify quality.
30.61%
Diluted EPS change of 30.61% versus flat Biotechnology. Walter Schloss would verify quality.
2.13%
Share count reduction below 50% of Biotechnology median of 0.18%. Jim Chanos would check for issues.
2.13%
Diluted share reduction below 50% of Biotechnology median of 0.16%. Jim Chanos would check for issues.